Contact SCGE




Gene Therapy Trial Report

Summary

A Study to Evaluate KRIYA-825 (VV-14295) in Adults With Geographic Atrophy Secondary to Age-related Macular Degeneration

NCTID NCT06765980 (View at clinicaltrials.gov)
Description
Development Status 🔄 Active
Indication Geographic Atrophy Secondary to Age-related Macular Degeneration
Disease Ontology Term 🔄 DOID:10871
Compound Name 🔄 KRIYA-825
Compound Alias 🔄 VV-14295
Sponsor Kriya Therapeutics, Inc.
Funder Type Industry
Recruitment Status
Enrollment Count 62 (ESTIMATED)
Results Posted Not Available

Therapy Information

Target Gene/Variant 🔄 CR2-CR1
Therapy Type 🔄 Gene transfer
Therapy Route 🔄 In-vivo
Mechanism of Action 🔄 Genetic delivery of therapeutic protein
Route of Administration 🔄 Suprachoroidal
Drug Product Type 🔄 Viral vector
Delivery System 🔄 Viral transduction
Vector Type 🔄 AAV2
Dose 1 🔄 Undisclosed

Study Record Dates

Current Stage Phase1, Phase2
Submit Date 2024-12-19
Completion Date 2027-12-15
Last Update 2025-12-09

Participation Criteria

Eligible Age 55 Years - 80 Years
Standard Ages Adult, Older adult
Sexes Eligible for Study ALL

Locations

No.of Trial Sites 2
Locations New Zealand,Canada

Regulatory Information

Has US IND True
FDA Designations
Recent Updates

Resources/Links

Preclinical Publications 🔄